




The relative strengths and weaknesses of Spero Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Spero Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 28% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	95,414
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,663
Liabilities, Non-Current	4,617
Other Assets	8,416
Other Compr. Net Income	44
Other Expenses	0
Other Liabilities	249
Other Net Income	2,291
Other Revenues	18,147
Property and Equipment	2,273
Research and Development	65,775
Selling, General and Administrative Expense	15,588

Output Variable	Value in 1000 USD
Assets	106,103
Liabilities	31,529
Expenses	81,363
Revenues	18,147
Stockholders Equity	74,574
Net Income	-60,925
Comprehensive Net Income	-60,903
BaseVar	119,738
ECR before Limited Liability	148%
Economic Capital Ratio	266%